Novo Nordisk tests the efficacy of its weight loss medication on alcoholic liver disease
老蟹2017
发表于 2024-5-15 17:18:05
1308
0
0
On May 15th, it was reported that Novo Nordisk is conducting trials on its weight loss drugs to explore whether they can reduce alcohol intake and treat alcoholic liver disease. The company is seeking to expand the use of these best-selling drugs.
CandyLake.com is an information publishing platform and only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
转播
You may like
- Lilly Weight Loss Medicine Approved by US FDA, Developed by Domestic Pharmaceutical Companies Press "Acceleration Key"
- Top 20 US Stock Deals: Pfizer Encounters Double Killing Lawsuit between Diet Drugs and COVID-19 Vaccine
- Johnson&Johnson CEO: Currently has no intention of producing weight loss drugs and focuses on expanding into fields such as neurology and oncology
- Can Smegglutide Help Quit Alcohol? Novo Nordisk's latest liver disease research will provide answers
- Lilly: We have applied to the FDA for the weight loss drug Zepbound to treat sleep apnea, and it is expected to be approved as early as the end of the year
- Novo Nordisk reaches settlement with Mylan Pharmaceuticals over patent dispute over weight loss drug Ozempic and Wegovy
